Literature DB >> 17904185

Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

M E Fluet1, A C Whitmore, D A Moshkoff, K Fu, Y Tang, M L Collier, A West, D T Moore, R Swanstrom, R E Johnston, N L Davis.   

Abstract

Genetic vaccines are engineered to produce immunogens de novo in the cells of the host for stimulation of a protective immune response. In some of these systems, antigens engineered for rapid degradation have produced an enhanced cellular immune response by more efficient entry into pathways for processing and presentation of MHC class I peptides. VEE replicon particles (VRP), single cycle vaccine vectors derived from Venezuelan equine encephalitis virus (VEE), are examined here for the effect of an increased rate of immunogen degradation on VRP vaccine efficacy. VRP expressing the matrix capsid (MA/CA) portion of SIV Gag were altered to promote rapid degradation of MA/CA by various linkages to co-translated ubiquitin or by destabilizing mutations and were used to immunize BALB/c mice for quantitation of anti-MA/CA cellular and humoral immune responses. Rapid degradation by the N-end rule correlated with a dampened immune response relative to unmodified MA/CA when the VRP carried a glycoprotein spike from an attenuated strain of VEE. In contrast, statistically equivalent numbers of IFNgamma(+)T-cells resulted when VRP expressing unstable MA/CA were packaged with the wild-type VEE glycoproteins. These results suggest that the cell types targeted in vivo by VRP carrying mutant or wild type glycoprotein spikes are functionally different, and are consistent with previous findings suggesting that wild-type VEE glycoproteins preferentially target professional antigen presenting cells that use peptides generated from the degraded antigen for direct presentation on MHC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904185      PMCID: PMC2288739          DOI: 10.1016/j.virol.2007.08.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Authors:  Joseph M Thompson; Alan C Whitmore; Jennifer L Konopka; Martha L Collier; Erin M B Richmond; Nancy L Davis; Herman F Staats; Robert E Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

2.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

Review 3.  Good research ideas for clinicians.

Authors:  Marianne Chulay
Journal:  AACN Adv Crit Care       Date:  2006 Jul-Sep

Review 4.  Impact of the N-terminal amino acid on targeted protein degradation.

Authors:  Thierry Meinnel; Alexandre Serero; Carmela Giglione
Journal:  Biol Chem       Date:  2006-07       Impact factor: 3.915

5.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

6.  Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens.

Authors:  T M Fu; L Guan; A Friedman; J B Ulmer; M A Liu; J J Donnelly
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

7.  Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.

Authors:  Y Wu; T J Kipps
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

Review 8.  The N-end rule: functions, mysteries, uses.

Authors:  A Varshavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

9.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

10.  Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells.

Authors:  Kevin P Nishimoto; Amanda K Laust; Kehui Wang; Kurt I Kamrud; Bolyn Hubby; Jonathan F Smith; Edward L Nelson
Journal:  Viral Immunol       Date:  2007       Impact factor: 2.257

View more
  4 in total

Review 1.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

2.  Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.

Authors:  Timothy Sheahan; Alan Whitmore; Kristin Long; Martin Ferris; Barry Rockx; William Funkhouser; Eric Donaldson; Lisa Gralinski; Martha Collier; Mark Heise; Nancy Davis; Robert Johnston; Ralph S Baric
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

3.  Packaging, Purification, and Titration of Replication-Deficient Semliki Forest Virus-Derived Particles as a Self-Amplifying mRNA Vaccine Vector

Authors:  Nastaran Sadat Savar; Thomas Vallet; Arash Arashkia; Kenneth Lundstrom; Marco Vignuzzi; Hamid Mahmoudzadeh Niknam
Journal:  Iran Biomed J       Date:  2022-07-01

4.  Fragmentation of SIV-gag vaccine induces broader T cell responses.

Authors:  Adel Benlahrech; Andrea Meiser; Shanthi Herath; Timos Papagatsias; Takis Athanasopoulos; Fucheng Li; Steve Self; Veronique Bachy; Catherine Hervouet; Karen Logan; Linda Klavinskis; George Dickson; Steven Patterson
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.